FDA Urged to Strengthen Warnings for Asthma Drug Singulair by New York Attorney General
Albany, New York – The New York attorney general’s office is urging the Food and Drug Administration (FDA) to take stronger actions against the use of an asthma drug known as montelukast, more commonly referred to as Singulair, due to concerns about its potential side effects, particularly in children. The Office of the Attorney General’s Health Care Bureau chief, Darsana Srinivasan, raised concerns in a letter to FDA Commissioner Robert Califf about the existing warnings …